Kymera Therapeutics, Inc. (KYMR) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Kymera Therapeutics, Inc.
Address
500 North Beacon Street
Watertown, MA 02472
United States of America (the)
Phone
857 285 5300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
273
First IPO Date
August 21, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director | 1.23M | 1979 |
| Bruce L. Booth DPHIL | Co-Founder & Independent Chairman | 70,000 | 1974 |
| Brian R. Adams | Chief Legal Officer & Corporate Secretary | 540,095 | 1974 |
| Noah Goodman | Chief Business Officer | 597,289 | 1987 |
| Bruce N. Jacobs | Chief Financial Officer | 795,250 | N/A |
| Jared A. Gollob | Advisor | 806,344 | 1965 |
| Jeremy G. Chadwick | Advisor | 806,344 | 1963 |
| Penny Carlson | Senior Vice President of Development Operations | 0 | N/A |
| Neil Graham MBBS | Chief Development Officer | 0 | 1959 |
| Brian Albarran | SVP of Corporate Strategy | 0 | N/A |
| Justine E. Koenigsberg | Vice President of Investor Relations | 0 | N/A |
| Karen Weisbach | Head of People & Culture | 0 | N/A |
| Juliet Williams | Head of Research | 0 | N/A |
Description
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
